drugset / Trial / NCT02661061

Ketamine for Relapse Prevention in Recurrent Depressive Disorder

NCT02661061

Phase 1 Terminated 9 enrolled St Patrick's Hospital, Ireland
RandomizedParallel-groupQuadruple-blindOther

Summary

Randomised, controlled, parallel-group, pilot clinical trial of ketamine vs. midazolam for depression relapse prevention in persons at high risk. The main purpose of the pilot study is to assess trial processes to help inform a future definitive trial.

Timeline

Start
2015-12
Primary completion
2018-05-23
Completion
2018-05-23

Drugs

EvaluationDrugModalityDoseRoute
Subject Ketamine Small molecule 0.05 mg/kg
Comparator Midazolam Small molecule 0.045 mg/kg